Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Yeh MW, Zhou H, Adams AL, Ituarte PHG, Liu IA, Haigh PI. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 2016:5 de abril. [Ref.ID 100114]
2. Cita con resumen
Anónimo. Sulfate de magnésium et grossesse: anomalies squelettiques foetales. Prescrire 2014;34:511. [Ref.ID 98074]
3.Tiene citas relacionadas
Gourlay ML, Lui L-Y, Ensrud KE. Bone-density testing interval and transition to osteoporosis. N Engl J Med 2012;366:1548. [Ref.ID 92771]
4.Tiene citas relacionadas Cita con resumen
Cheung AM, Papaioannou A. Bone-density testing interval and transition to osteoporosis. N Engl J Med 2012;366:1546. [Ref.ID 92768]
5.Enlace a cita original Cita con resumen
Erviti López J. Denosumab en fracturas osteoporóticas. Lectura crítica del ensayo FREEDOM. Boletín de Información Farmacoterapéutica de Navarra 2012;20:1-8. [Ref.ID 92630]
6. Cita con resumen
Voelker R. Osteoporosis screening may be needed less often than previously believed. JAMA 2012;307:654. [Ref.ID 92365]
7.Tiene citas relacionadas Cita con resumen
Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui L-Y, Ransohoff DF, Cauley JA, Ensrud KE, for the Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012;366:225-33. [Ref.ID 92235]
8. Cita con resumen
Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9. [Ref.ID 90243]
9.Enlace a cita original
Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:marzo. [Ref.ID 88032]
10.Enlace a cita original Cita con resumen
Garcia F, Montero Alonso MJ, Merino Senovilla A, Sanz Cantalapiedra R, Maderuelo JA. Las cifras mágicas en la prevención farmacológica de la enfermedad cardiovascular y de fracturas. Boletín de Información Farmacoterapéutica de Navarra 2009;17:49-63. [Ref.ID 87090]
11. Cita con resumen
Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO Trial): a randomized controlled trial. PLOS Medicine 2008;5:1462-72. [Ref.ID 84385]
12. Cita con resumen
Pack AM, Morell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008;70:1586-93. [Ref.ID 82854]
13.Tiene citas relacionadas Cita con resumen
Alonso-Coello P, López García-Franco A, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering?. BMJ 2008;336:126-9. [Ref.ID 82022]
14.
Eskandari F, Martínez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G, for the Premenopausal Osteoporosis Women Alendronate Depression (POWER) Study Group. Low bone mass in premenopausal women with depression. Arch Intern Med 2007;167:2329-36. [Ref.ID 81641]
15.
Anónimo. Ostéodensitométrie chez les femmes ménopausées en bonne santé. Prescrire 2007;27:516-21. [Ref.ID 80444]
16. Cita con resumen
Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D'Anna R, Cannata ML, Corrado F, Adamo EB, Wilson S, Squadrito F. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. A randomized trial. Ann Intern Med 2007;146:839-47. [Ref.ID 80393]
17. Cita con resumen
Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. A randomized trial. Ann Intern Med 2007;146:416-24. [Ref.ID 79710]
18.
Anónimo. Medroxyprogesterone. Loss of bone mineal density. Canada. WHO Pharmaceuticals Newsletter 2005;4:3. [Ref.ID 75429]
Seleccionar todas
 
 1 a 18 de 18